ArticleScientific reports2025
Genomic surveillance of SARS-CoV-2 variants using pooled WGS.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methods for safely sharing dual-use genetic data.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study presents the development and validation of a genomic surveillance strategy using Whole Genome Sequencing (WGS) on normalized pooled samples to detect and monitor SARS-CoV-2 variants. A bioinformatics pipeline was designed specifically for analyzing pooled WGS data and was validated using simulated datasets, pooled samples of reference materials, and pooled clinical samples collected during key periods of the Delta and Omicron variant emergence. The approach was evaluated for its accuracy in estimating variant abundance at both the Phylogenetic Assignment of Named Global Outbreak (PANGO) lineage level and the World Health Organization (WHO) variant level. From the simulation datasets, the method achieved an overall sensitivity of 99.1% and a positive predictive value (PPV) of 99.9% for detecting SARS-CoV-2 variants at the WHO variant level. At the PANGO lineage level, it achieved an overall sensitivity of 82.8% and a PPV of 77.4% when a predicted lineage was considered accurate if it shared more than 90% of markers with any true lineage present in the pooled sample. The accuracy of variant abundance estimation was further validated using pooled samples of reference materials. Analysis of pooled clinical samples showed results consistent with national epidemiological trends, particularly during the emergence of the Delta and Omicron variants in Korea. This pooled WGS-based genomic surveillance strategy offers a scalable and economical solution for monitoring SARS-CoV-2 variants, providing public health authorities with a valuable tool for tracking pandemic dynamics and enabling timely responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.